NFE2L2 and cancer: Within the top 25 pathways was also negative regulation of NOTCH4 signalling—which is associated with PCa disease progression and prognosis [65], NFE2L2-mediated nuclear events, regulation of mRNA stability, G2/M progression, MAPK6/MAPK4 signalling—which is an important player in cancer development [66], BTRC:CUL1-mediated degradation of NFE2L2, and GSK3B—which has been highlighted as a treatment target in PCa [67].